WebDec 12, 2024 · RVd followed by high-dose therapy (HDT), autologous stem cell transplant (ASCT), and consolidation is a SoC regimen for US pts with NDMM. This phase 2, randomized study (GRIFFIN; NCT02874742) evaluated DARA plus RVd (D-RVd) in ASCT-eligible NDMM pts. A 16-pt safety run-in showed no safety concerns. WebThe phase II GRIFFIN study evaluated whether the addition of daratumumab to VRd, a monoclonal CD38 antibody, followed by ASCT, could further enhance the depth of response in newly diagnosed MM. ... (OS) in NDMM patients undergoing autologous stem cell transplant (ASCT). The phase II GRIFFIN study (MMY2004, NCT02874742) evaluated …
New Clinical and Real-World Data Support Use of …
WebFeb 24, 2024 · During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Jacob Laubach 1 presented an update of the phase II GRIFFIN trial … WebJun 13, 2024 · “The optimal daratumumab-containing maintenance regimen remains to be determined,” Moreau said. “We looked forward to the results of ongoing trials such as … dickinson ck212tp 12ga shotgun
New DARZALEX® (daratumumab) Data from GRIFFIN …
WebJan 12, 2024 · (different to GRIFFIN [NCT02874742], PERSEUS [NCT03710603], CEPHEUS [NCT03652064], or other trials). ATLAS is a key trial suggesting that maintenance approaches with more than one drug, including lenalidomide, should be … WebSep 13, 2024 · The frequency of daratumumab dosing every 4 weeks of is currently being investigated in the phase 2 GRIFFIN study (NCT02874742) and the phase 3 PERSEUS (NCT03710603), AURIGA (NCT03901963), … WebNov 5, 2024 · The phase 2 randomized GRIFFIN study (NCT02874742) evaluates frontline DARA in combination with lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible NDMM. In the primary analysis, ... In GRIFFIN, 93.7% of D-RVd pts and 98.8% of RVd pts reached the minimum institutional CD34 + threshold to perform a … dickinson clan